2025 · 3rd Quarter (July 1 - Sep 30)
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Literal source text
Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use; H.R.4273/S.2292, Over-the-Counter Monograph Drug User Fee Amendments; H.R.5371, Continuing Appropriations and Extensions Act, 2026.
Literal federal measure citations: H.R.4273, S.2292, H.R.5371
Issues related to coverage of over-the-counter products with FSAs and HSAs.
Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166).
Literal federal measure citations: H.R.5166
Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
